Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Psyence Biomedical Ltd. Warrant (PBMWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PBMWW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.37% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 25422 | Beta -0.45 | 52 Weeks Range 0.00 - 0.13 | Updated Date 03/18/2025 |
52 Weeks Range 0.00 - 0.13 | Updated Date 03/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -137.79% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 452803 |
Shares Outstanding - | Shares Floating 452803 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Psyence Biomedical Ltd. Warrant
Company Overview
History and Background
Psyence Biomedical Ltd. is a life science biotechnology company focused on understanding and addressing the significant unmet needs of mental health and neurological disorders. The warrants represent the right to purchase shares of Psyence Biomedical Ltd. Details of the warrants, including exercise price and expiry date are required for further background
Core Business Areas
- Psychedelic Drug Development: Developing and commercializing psychedelic-based treatments for mental health disorders.
- Research and Clinical Trials: Conducting research and clinical trials to validate the efficacy and safety of their treatments.
- Intellectual Property: Building a strong portfolio of intellectual property related to psychedelic compounds and therapies.
Leadership and Structure
Details on the leadership team and organizational structure for Psyence Biomedical Ltd. would need to be found from various sources. The warrant itself does not have a team, it's a financial derivative of the company.
Top Products and Market Share
Key Offerings
- Psychedelic Therapies (future): Psyence is developing psychedelic-based therapies for conditions like anxiety and depression. Market share is currently negligible as products are in development. Competitors include Atai Life Sciences, Compass Pathways (CMPS), and MindMed (MNMD).
- Research Programs (future): Psyence engages in research programs to explore the therapeutic potential of psychedelics. Revenue from research is limited at this stage and comes from potential partnerships and grants. Competitors are academic institutions and other biotech companies like the ones above.
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging, driven by increasing recognition of mental health challenges and the limitations of existing treatments. There's growing acceptance of psychedelics for therapeutic use, leading to increased investment and research.
Positioning
Psyence Biomedical Ltd. is positioned as a key player in the development and commercialization of psychedelic therapies. It is competing with other companies for funding, clinical trial results, and regulatory approvals.
Total Addressable Market (TAM)
The TAM for mental health treatments is significant, estimated to be in the billions of dollars. Psyence is targeting a portion of this market with its novel psychedelic therapies, the size of which depends on regulatory approvals and treatment adoption rates.
Upturn SWOT Analysis
Strengths
- Focus on psychedelic medicine
- Strong research and development capabilities
- Potential for breakthrough treatments
- Intellectual property portfolio
Weaknesses
- Early stage company
- Dependence on regulatory approvals
- Limited commercialization experience
- High cash burn rate
Opportunities
- Growing market for mental health treatments
- Increasing acceptance of psychedelics
- Potential partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Negative public perception of psychedelics
- Risk of clinical trial failures
Competitors and Market Share
Key Competitors
- CMPS
- MNMD
- ATAI
Competitive Landscape
Psyence Biomedical faces competition from other psychedelic medicine companies and established pharmaceutical players. Success depends on its ability to develop and commercialize effective therapies, secure funding, and navigate the regulatory landscape.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in its early stages. Focus is on R&D and clinical trials.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of psychedelic therapies. Analyst estimates are unavailable without further information
Recent Initiatives: Recent initiatives would include clinical trial progress, partnerships, and fundraising activities. Specific details would require up-to-date information.
Summary
Psyence Biomedical Ltd. Warrant represents a high-risk, high-reward investment tied to the success of Psyence Biomedical's psychedelic drug development efforts. The company is in an early stage and faces regulatory and competitive hurdles. Strong clinical trial results and successful commercialization will be key to its growth and profitability. Investors should be aware of the inherent risks associated with early-stage biotech companies.
Similar Companies
ATAI
ATAI Life Sciences BV
ATAI
ATAI Life Sciences BV
CMPS
Compass Pathways Plc
CMPS
Compass Pathways Plc
MNMD
Mind Medicine Inc
MNMD
Mind Medicine Inc
Sources and Disclaimers
Data Sources:
- Company website
- Public filings (SEC if US traded)
- Industry reports
- Analyst reports (if available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. The information provided is based on publicly available information and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Warrant
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-26 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.psyencebiomed.com |
Full time employees - | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.